AOA Dx Closes $7 million Funding Round to Bring the First Accurate Early Detection Test for Ovarian Cancer to Market

AOA Dx Inc is proud to announce that they have closed both of their seed rounds totaling a $7 million funding round led by Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent and other notable investors.

The funding will be used to further develop the next generation of AOA’s ovarian cancer detection technology, AKRIVIS GD™ and expand their growing team. Currently, there are no reliable ovarian cancer biomarkers that detect early stage disease.

AOA Dx Welcomes Women’s Health Industry Leader Surbhi Sarna as an Independent Board Member

AOA Dx is excited to announce the appointment of Surbhi Sarna as an Independent Board Member. Sarna is most recently known for becoming Y Combinator’s first-ever partner for healthcare and biotech.

Sarna is the founder and former CEO of nVision Medical, a medical device company that to date, is the only device cleared by the FDA to collect cells from the fallopian tube, the known site of the most lethal forms of ovarian cancer. nVision Medical was acquired by Boston Scientific in 2018 for $275 million.

AOA Dx Featured in The Journal of Precision Medicine

AOA Dx Inc is proud to annouce that they were featured in “The Journal of Precision Medicine, titled “Tumor Glycolipids, a New Frontier for Early Detection and Precision Medicine in Ovarian Cancer and Other Malginancies”. The paper was authored by AOA’s Chief Scientific Officer H. Uri Saragovi, PHD, AOA’s Co-Founder and Chief Business Officer Anna Milik Jeter and Samantha A. Yee, a PhD cancidate at UT San Antonio.